Viz.ai and Alnylam Pharmaceuticals Partner to Launch AI Care Pathway for Cardiac Amyloidosis

Why It Matters

The automated pathway could dramatically shorten the time from detection to treatment, improving survival for patients with ATTR‑CM and AL amyloidosis. It also demonstrates how AI can embed diagnostic intelligence directly into routine imaging, reshaping care coordination across the health system.

Key Takeaways

• AI flags cardiac amyloidosis without physician suspicion
• Uses FDA‑cleared Us2.ai echocardiography algorithm
• Automates referral and testing workflow
• Pilot across multiple sites, scaling to 2,000+ hospitals
• Aims to cut time‑to‑treatment for ATTR‑CM and AL

Pulse Analysis

Cardiac amyloidosis, encompassing ATTR‑CM and AL subtypes, remains a diagnostic blind spot because its symptoms mimic generic heart failure. Patients often endure months of ineffective therapy before a definitive diagnosis, missing the narrow window where disease‑modifying treatments can alter outcomes. Early identification is therefore a critical unmet need, and health systems are scrambling for tools that can sift through routine imaging without adding clinician workload.

Artificial intelligence has matured from experimental prototypes to clinically validated solutions, and Viz.ai sits at the forefront of this transition. By integrating the FDA‑cleared Us2.ai echocardiography algorithm with deep electronic health‑record connectivity and generative AI, the new care pathway continuously scans standard echo studies for the subtle patterns indicative of amyloid deposition. Once flagged, the system automatically triggers a cascade—order confirmatory scintigraphy or biopsy, schedule a cardiology‑specialist consult, and set up longitudinal follow‑up—thereby eliminating the reliance on a physician’s intuition alone.

The partnership with Alnylam, a leader in RNA‑interference therapeutics, adds strategic depth. As Alnylam’s drugs target the underlying protein misfolding, a faster diagnostic funnel directly expands the treatable patient pool, potentially accelerating market adoption and improving real‑world outcomes. Moreover, scaling the pilot to Viz.ai’s 2,000‑plus hospital network could generate robust data on time‑to‑treatment reductions and cost savings, setting a precedent for AI‑enabled pathways in other rare, high‑mortality conditions. This convergence of AI diagnostics and targeted therapy exemplifies a new model of precision care delivery.